74,704 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the second quarter, Holdings Channel.com reports. The firm acquired 74,704 shares of the company’s stock, valued at approximately $592,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Xeris Biopharma in the second quarter valued at about $115,042,000. Vanguard Group Inc. raised its position in shares of Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after purchasing an additional 1,358,760 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Xeris Biopharma by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after purchasing an additional 135,815 shares during the last quarter. State Street Corp lifted its stake in Xeris Biopharma by 10.1% in the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after buying an additional 378,595 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in Xeris Biopharma by 6.0% in the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after buying an additional 185,063 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Price Performance

Shares of XERS stock opened at $8.53 on Monday. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The firm’s 50-day moving average is $8.41 and its two-hundred day moving average is $6.98. Xeris Biopharma Holdings, Inc. has a 12 month low of $5.25 and a 12 month high of $10.08. The company has a market capitalization of $1.56 billion, a PE ratio of -77.55 and a beta of 0.70.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. Analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on XERS. Barclays lifted their price objective on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen lowered Xeris Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $12.00.

Insider Activity

In related news, insider Beth Hecht sold 16,666 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total value of $141,494.34. Following the completion of the transaction, the insider directly owned 1,127,796 shares in the company, valued at approximately $9,574,988.04. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 15,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total value of $127,350.00. Following the sale, the insider directly owned 1,639,208 shares of the company’s stock, valued at approximately $13,916,875.92. This trade represents a 0.91% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 224,998 shares of company stock valued at $1,847,219. 4.35% of the stock is currently owned by company insiders.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.